| Bioactivity | Tigatuzumab (CS-1008) is a humanized IgG1 monoclonal antibody targets death receptor 5 (DR5). Tigatuzumab induces cell apoptosis of cancer cells and inhibits tumor growth in vivo. Tigatuzumab can be used for the research of cancer[1]. |
| Invitro | Tigatuzumab 对 MIA PaCa-2 细胞和 BxPC-3 细胞敏感，IC50 值分别为 2.95 和 8.21 μg/mL[1]。Tigatuzumab (3-8 μg/mL; 5 h) 诱导癌细胞凋亡[1]。 Apoptosis Analysis[1] Cell Line: |
| In Vivo | Tigatuzumab (3mg /kg；静脉注射；每周一次，共 4 周) 有效抑制人胰腺癌 MIA PaCa-2-RFP 原位小鼠模型的肿瘤生长[1]。 Animal Model: |
| Name | Tigatuzumab |
| CAS | 918127-53-4 |
| Molar Mass | 144.6 (kDa) |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Yamamoto J, et al. Oral recombinant methioninase increases TRAIL receptor-2 expression to regress pancreatic cancer in combination with agonist tigatuzumab in an orthotopic mouse model. Cancer Lett. 2020 Nov 1;492:174-184. |